WANBURY
Wanbury share price & financials
- Price
- ₹332.2
- Market cap
- ₹837 Cr
- Sector
- Healthcare
What Wanbury Limited does
Wanbury manufactures Active Pharmaceutical Ingredients (APIs) at two plants in Tanuku (Andhra Pradesh) and Patalganga (Maharashtra), producing molecules such as Metformin (antidiabetic), Sertraline (antidepressant), Tramadol (pain management), Paroxetine, Mefenamic acid and Diphenhydramine, sold mostly to regulated export markets. It also runs a legacy branded Formulations business in India, marketing acute-therapy products across anti-cold & cough, pain/anti-inflammatory, antacid and supplement categories under an outsourced (contract) manufacturing model, distributed through its own field force, C&F agents and distributor network.
Segments
- API (Active Pharmaceutical Ingredients)
- Formulations
- Manufacturing plants
- 2 API plants (Tanuku, Andhra Pradesh & Patalganga, Maharashtra)
- Cumulative installed reactor capacity
- 500 KL (400 KL at Tanuku + 96 KL at Patalganga)
- API molecule portfolio
- 6 molecules (Metformin, Sertraline, Tramadol, Paroxetine, Mefenamic acid, Diphenhydramine) + 1 new anaesthetic
- USFDA-approved API facilities
- 2
- Global regulatory approvals
- US-FDA, EDQM (Europe), ANVISA (Brazil), KFDA (South Korea), COFEPRIS (Mexico), WHO-GMP
- DMF/CEP filings with regulatory authorities
- 70 total (64 approved, 6 pending)
Quarterly results
Q1 FY27: revenue up 1.5%, net profit down 76.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 161 | 133 | 172 | 163 | 160 −1% | 162 +22% | 165 −4% | 166 +1% |
| EBITDA | 20 | 14 | 30 | 24 | 26 +29% | 27 +91% | 30 +1% | 16 −34% |
| Net profit | 8 | 1 | 20 | 13 | 15 +89% | 16 +1192% | 22 +7% | 3 −76% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −10.1% 1Y
1Y: ₹266.1 on 10 Sept 2025 → ₹239.35. High ₹344.75 (15 Jul 2026), low ₹163.34 (27 Jan 2026).
Financials, as filed
Revenue grew 9.2% a year over 3 years, FY23 to FY26. Operating margin widened to 16.4%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹500 Cr | ₹576 Cr | ₹598 Cr | ₹650 Cr |
| Operating profit | ₹23 Cr | ₹70 Cr | ₹75 Cr | ₹107 Cr |
| Operating margin | 4.6% | 12.2% | 12.5% | 16.4% |
| Interest | ₹22 Cr | ₹29 Cr | ₹37 Cr | ₹30 Cr |
| Depreciation | ₹12 Cr | ₹13 Cr | ₹13 Cr | ₹14 Cr |
| Net profit | ₹-10 Cr | ₹30 Cr | ₹31 Cr | ₹66 Cr |
| Net margin | -2.0% | 5.3% | 5.1% | 10.2% |
| Cash from operations | ₹20 Cr | ₹5 Cr | ₹26 Cr | — |
| Free cash flow | ₹7 Cr | ₹-9 Cr | ₹-22 Cr | — |
| ROCE | 17.0% | 58.0% | 34.0% | 31.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹25 Cr | ₹33 Cr | ₹33 Cr | ₹33 Cr | ₹33 Cr | ₹35 Cr |
| Reserves | ₹-156 Cr | ₹-30 Cr | ₹-40 Cr | ₹-5 Cr | ₹26 Cr | ₹110 Cr |
| Borrowings | ₹166 Cr | ₹74 Cr | ₹68 Cr | ₹116 Cr | ₹179 Cr | ₹224 Cr |
| Other liabilities | ₹253 Cr | ₹275 Cr | ₹241 Cr | ₹199 Cr | ₹176 Cr | ₹149 Cr |
| Total liabilities | ₹288 Cr | ₹351 Cr | ₹302 Cr | ₹343 Cr | ₹414 Cr | ₹518 Cr |
| Fixed assets | ₹167 Cr | ₹167 Cr | ₹167 Cr | ₹167 Cr | ₹201 Cr | ₹229 Cr |
| Capital work in progress | ₹11 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹5 Cr | ₹25 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹109 Cr | ₹182 Cr | ₹133 Cr | ₹173 Cr | ₹208 Cr | ₹263 Cr |
| Total assets | ₹288 Cr | ₹351 Cr | ₹302 Cr | ₹343 Cr | ₹414 Cr | ₹518 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters added +3.38 pp while the public trimmed −2.75 pp. The shareholder count shrank 4% to 17,174.
- Promoters
- 43.0%
- FIIs
- 0.9%
- DIIs
- 0.1%
- Public
- 56.0%
Since Jun 2025
- Promoters +3.38 pp
- Public −2.75 pp
- FIIs −0.70 pp
How it drifted, 12 quarters
Over this window the public fell from 60.2% to 56.0% — −4.2 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 39.8%, Public 60.2%.Dec '23: Promoters 39.8%, Public 60.2%.Mar '24: Promoters 39.8%, FIIs 0.2%, Public 60.0%.Jun '24: Promoters 39.8%, FIIs 0.2%, Public 60.0%.Sep '24: Promoters 39.8%, FIIs 1.0%, Public 59.2%.Dec '24: Promoters 39.8%, FIIs 0.8%, Public 59.4%.Mar '25: Promoters 39.8%, FIIs 1.6%, Public 58.7%.Jun '25: Promoters 39.6%, FIIs 1.6%, Public 58.8%.Sep '25: Promoters 43.1%, FIIs 0.8%, Public 56.1%.Dec '25: Promoters 43.1%, FIIs 0.7%, Public 56.2%.Mar '26: Promoters 43.0%, FIIs 0.6%, Public 56.4%.Jun '26: Promoters 43.0%, FIIs 0.9%, DIIs 0.1%, Public 56.0%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Zaki Abbas Nasser +0.11 pp 1.76% held
- Basava Sankararao Kolli +0.11 pp 1.16% held
The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Wanbury Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Expert Chemicals (India) Pvt Ltd | 34.36% | unchanged |
| Kingsbury Investments Inc | 8.65% | unchanged |
| Suresh Bhatia | 3.11% | unchanged |
| Authum Investment & Infrastructure Lmited NBFC / DFI | 2.07% | unchanged |
| Zaki Abbas Nasser | 1.76% | +0.11 pp |
| Sharmin Nasser | 1.33% | −0.06 pp |
| Basava Sankararao Kolli | 1.16% | +0.11 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Wanbury Limited
Guides on how to read this kind of business and the numbers that matter.